CN1739538A - Suppository for teating mycotic vaginitis - Google Patents
Suppository for teating mycotic vaginitis Download PDFInfo
- Publication number
- CN1739538A CN1739538A CN 200510010343 CN200510010343A CN1739538A CN 1739538 A CN1739538 A CN 1739538A CN 200510010343 CN200510010343 CN 200510010343 CN 200510010343 A CN200510010343 A CN 200510010343A CN 1739538 A CN1739538 A CN 1739538A
- Authority
- CN
- China
- Prior art keywords
- suppository
- tinidazole
- vagina
- nystatin
- chlorhexidine acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The suppository for treating mycotic vaginitis contains tinidazole, fungicidin and chlorhexidine in certain proportion, and is prepared through mixing tinidazole, fungicidin and chlorhexidine in certain proportion in some container and filling into administration unit with each suppository weighing 0.5 g. The suppository is administrated via vagina and absorbed through mucous membrane to kill fungi in vagina. It may also promote the proliferation of epidermis cell in vagina, regulate pH value in vagina, raise antifungus capacity, improve the permeability of cell membrane and reduce exudation and has no negative effect.
Description
Technical field
The present invention relates to a kind of Western medicine suppository.
Background technology
Colpitis mycotica belongs to frequently-occurring disease, high morbidity in gynaecopathia.According to statistics, in the adult women, nearly 1/3rd this disease of the infected mistake of women is arranged, mainly the swimming tool by unclean sexual intercourse, the bad bathhouse of sterilization, shared bathroom facilities, taxi, IPN underwear etc. infect this disease.Though colpitis mycotica is threat to life not, it brings painful topic to the patient.Because ill privileged sites, majority are reluctant again to seek medical advice, and this disease is taken great pains to guard a secret especially.Institute is so that course of disease lengthening, and the state of an illness increases the weight of, and particularly to summer, savours greatlyyer again, has more increased the weight of patient's psychological burden.Work that has influence on that has even man and wife's harmony, family's wellbeing.The types of drugs that is used for the treatment of colpitis mycotica in the market is fewer, and prescription is single, and curative effect is relatively poor, and there is recurrence one or two moon of general drug withdrawal more.Particularly long-term prescription also is easy to generate drug resistance.Make the patient lose treatment confidence.
Summary of the invention
The objective of the invention is, weak curative effect few, easily recur, be easy to generate chemical sproof problem, a kind of suppository for the treatment of colpitis mycotica is provided for the types of drugs that solves existing treatment colpitis mycotica.The present invention by tinidazole (Tinidazole), nystatin (Nystain) and chlorhexidine acetate by weight and standard (unit) make; Tinidazole is that 1800～2100 grams, nystatin are that 13～180,000 units, chlorhexidine acetate are 8～12 milligrams.Manufacture method of the present invention is: described tinidazole, nystatin and chlorhexidine acetate are put into to pack into after container stirs by above-mentioned weight and unit be suppository of the present invention to stype, every bolt weight is 0.5 gram.
Pharmacodynamic analysis of the present invention is as follows:
1, clinical data: whole pathology are all through gynecological and vaginal secretions plate coating checking, and reference " modern doctor trained in Western medicine gynecology " (cattle is built the license-master and compiles, China Science Tech Publishing House, 1996,211) is made a definite diagnosis.60 examples are divided into suppository treatment group (being called for short the treatment group) 30 examples, 20～49 years old age, average 33.6 years old, the course of disease 1～16 month, average 67 days at random.Western medicine matched group (abbreviation matched group) 30 examples, 23～48 years old age, average 31.2 years old, the course of disease 2～17 months, average 58 days.Clinical manifestation is that pruritus vulvae, causalgia, leucorrhea are many, color white matter stiff has piece or is the bean dregs shape.Two groups of data are learned processing there are no significant on age, the course of disease, the state of an illness difference (P＞0.05) by statistics, have comparability.
2, Therapeutic Method:
(1) treatment group: carry out intravaginal administration with medicine of the present invention, every night once, each 0.5 gram.
(2) matched group: nystatin 50u levigation incapsulates, and every night once, fills in vagina.Two groups of equal continuous uses, 10 days is 1 course of treatment.Viewing duration other associated treatment medicines of stopping using.Curative effect relatively Ridit is analyzed.
3, observing effect:
(1) criterion of therapeutical effect: produce effects: subjective symptoms and sign disappear, and the woman examines the vagina checking disappears continuous three the no mycetes of vaginal secretions plate coating checking.Effectively: subjective symptoms and sign obviously alleviate, and the woman examines colpitis and improves, and vagina cleanness degree takes a turn for the better and the vaginal secretions plate coating checking has only and finds mycete 1 time.Invalid: clinical symptoms and sign, woman's inspection and vaginal secretion plate coating checking all do not have change or increase the weight of.
(2) therapeutic effect: treatment is organized in 30 examples, produce effects 17 examples, effective 11 examples, invalid 2 examples, total effective rate 93.3%.In the matched group, produce effects 9 examples, effective 10 examples, invalid 11 examples, 63.3%, two group of obvious effective rate of total effective rate, total effective rate more all have significant difference (p＜0.05).
(3) follow the tracks of and to follow up a case by regular visits to: 17 routine patients of produce effects in the treatment group are healed to follow the tracks of later six months follow up a case by regular visits to and carried out routine examination, do not find 1 example recurrence.
4, discuss: colpitis mycotica is mainly due to the candida albicans infection, and is low with body disease-resistant power, estrogen secretion, and glycogenolysis, the imbalance of physiological functions such as vagina acid-base value pH value is relevant.Tinidazole, nystatin and chlorhexidine acetate are made the suppository intravaginal administration, by mucosa absorption, can suppress and can kill the fungus of deep and shallow table portion.Directly act on diseased region, have the vaginal epithelial cell of promotion hypertrophy, make the vagina pH value obtain adjusting, strengthen antibacterial ability, improve the permeability of cell membrane, minimizing is oozed out, and helps the effect that local inflammation absorbs.And do not see untoward reaction during the medication.Obviously be better than the comparative observation of matched group (P＜0.05) from the total effective rate of treatment group, the present invention have component rationally, determined curative effect, the advantage that do not recur after more.
The specific embodiment
The specific embodiment one: present embodiment by tinidazole (Tinidazole), nystatin (Nystain) and chlorhexidine acetate by weight and standard (unit) make; Tinidazole is that 1800～2100 grams, nystatin are that 13～180,000 units, chlorhexidine acetate are 8～12 milligrams.Manufacture method of the present invention is: described tinidazole, nystatin and chlorhexidine acetate are put into to pack into after container stirs by above-mentioned weight and unit be suppository of the present invention to stype, every bolt weight is 0.5 gram.
The specific embodiment two: present embodiment is made with unit by weight by tinidazole, nystatin and chlorhexidine acetate; Tinidazole is that 1850～2050 grams, nystatin are that 14～16.5 ten thousand units, chlorhexidine acetate are 9～11 milligrams.Other method is identical with the specific embodiment one.
The specific embodiment three: present embodiment is made with unit by weight by tinidazole, nystatin and chlorhexidine acetate; Tinidazole is that 2000 grams, nystatin are that 150,000 units, chlorhexidine acetate are 10 milligrams.Other method is identical with the specific embodiment one.
Claims (3)
1, a kind of suppository for the treatment of colpitis mycotica is characterized in that it is made with unit by weight by tinidazole, nystatin and chlorhexidine acetate; Tinidazole is that 1800～2100 grams, nystatin are that 13～180,000 units, chlorhexidine acetate are 8～12 milligrams.
2, a kind of suppository for the treatment of colpitis mycotica according to claim 1 is characterized in that it is that 1850～2050 grams, nystatin are that 14～16.5 ten thousand units, chlorhexidine acetate are 9～11 milligrams and make by tinidazole.
3, a kind of suppository for the treatment of colpitis mycotica according to claim 1 is characterized in that it is that 2000 grams, nystatin are that 150,000 units, chlorhexidine acetate are 10 milligrams and make by tinidazole.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510010343 CN1739538A (en) | 2005-09-16 | 2005-09-16 | Suppository for teating mycotic vaginitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510010343 CN1739538A (en) | 2005-09-16 | 2005-09-16 | Suppository for teating mycotic vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1739538A true CN1739538A (en) | 2006-03-01 |
Family
ID=36092162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510010343 Pending CN1739538A (en) | 2005-09-16 | 2005-09-16 | Suppository for teating mycotic vaginitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1739538A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048729A (en) * | 2011-01-08 | 2011-05-11 | 广州固志医药科技有限公司 | Preparation for treating vaginitis |
| CN101623251B (en) * | 2009-08-11 | 2011-06-22 | 湖北穆兰同大科技有限公司 | Gynecological antibacterial gel bionic propellant |
| CN109010259A (en) * | 2018-10-18 | 2018-12-18 | 韩晓东 | A kind of antimycotic and antibacterial compound preparation and preparation method thereof |
-
2005
- 2005-09-16 CN CN 200510010343 patent/CN1739538A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101623251B (en) * | 2009-08-11 | 2011-06-22 | 湖北穆兰同大科技有限公司 | Gynecological antibacterial gel bionic propellant |
| CN102048729A (en) * | 2011-01-08 | 2011-05-11 | 广州固志医药科技有限公司 | Preparation for treating vaginitis |
| CN102048729B (en) * | 2011-01-08 | 2012-08-08 | 广州固志医药科技有限公司 | Preparation for treating vaginitis |
| CN109010259A (en) * | 2018-10-18 | 2018-12-18 | 韩晓东 | A kind of antimycotic and antibacterial compound preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101049415A (en) | Preparation of Chinese traditional medicine for treating inflammation of department of gynecology | |
| CN103301502A (en) | Gynecological medical gel dressing and preparation method thereof | |
| CN104147108A (en) | Brown alginate oligosaccharide-containing antibacterial gel | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN102085248B (en) | Traditional Chinese medicinal composition for treating cervix diseases, method for preparing same and method for detecting same | |
| CN1739538A (en) | Suppository for teating mycotic vaginitis | |
| CN102755563B (en) | Traditional Chinese medicine composition for treating chronic prostatitis and preparation method thereof | |
| CN102485239B (en) | Chinese herbal composition used for treating gynecological inflammation | |
| CN101623368A (en) | Drug for treating gynecological diseases and preparation technology thereof | |
| CN105749260B (en) | Lysozyme hydrochloride vaginal tablet and preparation method and application thereof | |
| CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN1739754A (en) | Lotion for treating mycotic vaginitis | |
| CN101618051B (en) | Novel medicinal use of active parts of abelmoschus manihot general flavones | |
| CN107823442B (en) | Hemostatic and anti-infectious pharmaceutical composition | |
| CN102018805B (en) | Drug for treating relapsable vulvovaginal candidiasis | |
| CN1120442A (en) | Pudenda lotion and its prepn. method | |
| CN103536706B (en) | A kind of Chinese medicine for the treatment of trimester of pregnancy monilial vaginitis smokes lotion | |
| CN102670807A (en) | Medicine composition for treating prostatitis and preparation method and application thereof | |
| CN106902175A (en) | A kind of Chinese medicine ointment for treating perianal eczema | |
| CN107028874A (en) | External-applied ointment | |
| Haddadi et al. | Evaluation of The Effects of Vitamin C on Epithelialization of Burn Wounds | |
| CN101978968B (en) | Medicament for treating tympanitis | |
| CN1137917A (en) | Compound jiabing ear drops and preparation method thereof | |
| CN112618575A (en) | anti-HPV lactic acid bacteria gynecological mousse lotion and application thereof | |
| Haddadi et al. | Evaluation of the effects of Vitamin C on Epithelialization of Burn Wounds: A Randomized Clinical Trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |